Medicxi pioneered the asset-centric venture model over a decade ago, concentrating capital and decision-making on a single lead asset in each company rather than funding broad platforms, and operates as an integrated early-stage plus growth platform that can back European biotech companies from inception through late-stage clinical development and commercialization. The firm was formed by spinning out Index Ventures' entire life-sciences franchise and maintains formal backing from multiple global pharmas including GlaxoSmithKline, Johnson & Johnson Innovation, and Novartis as fund investors.